|
|
Index of Articles From 1995 TAGlines
- December, 1995
- CMV's Real World
When Two Prophylaxis Studies Declare Opposite Findings, Clinicians And Their Patients Are Lost in the Quandary - A question of patient management
- Giving Away the Farm
How Corporate Cynicism, Savvy Schmoozing and Relentless PR Paved The Way to Unqualified Approval for Two New Antiretrovirals - "Grave disservice to the public health"
- Random Gleanings
Tracking down the elusive CD8 cell factor, FDA panel recommends approval for ganciclovir implant, FDA approval for saquinavir; Lottery for ritonavir
- Subsctiption Information
- November, 1995
- Antiretroviral Horizon
35th Interscience Conference Unveils Results from Several Important Clinical Studies - Protease and paradox
- I'll Take Los Angeles
AIDS Treatment Activists from Across the Land Gather to Share Expertise and Ideas - "A conversation long overdue"
- Random Gleanings
FDA Antiviral Drugs Advisory Committee, Ambushed in the FDCs, Expanding T cells: Koenig weighs in on Good CTLs/Bad CTLs debate
- October, 1995
- "Kiss My Access"
Community Envoy to Food and Drug Panel Urges Caution in Approving New Anti-HIV Therapueutics and in Providing Early Access - "Badgering, hijacking activists"
- Reversal of Fortune
Despite Pressure to Crown Combo King, 175 Investigators Soft-Pedal Combination Nucleoside Study's Startling Findings - The didanosine surprise
- Washington Woes
Senate Appropriations Committee, the OAR's blue-ribbon review of the NIH AIDS program, TAG's Gregg Gonsalves, AmFAR Public Policy Director Jane Silver
- Conclusions for ACTG 175
- September, 1995
- August, 1995
- Science South of the Border
Feel Good Merck Meeting Leaves Everybody Agreeing, But Brazil Study Bodes Ill for the Future - Wrangling over control arm
- Diversity Threshold
New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome - Sloppy RT, Bane of All
- April, 1995
- Integrase: The Next Viral Target
With Two Down And Integrase On Deck, AIDS Research Team Hopes For a Hit--Or Will It Be 'Three Up, Three Down?'
- The Doxil NDA
FDA's Oncological Drug Advisory Committee Recommends DOX-SL for Accelerated Approval--But Not Without A Fight
- March, 1995
- Random Gleanings
FDA Just Says "No" To Salk Immunogen, Heralding the Naked Emperor (Part II), OAR's Dr. Paul Speaks, Varmus Selects New Director for Office of Alternative Medicine
- Dr. Emini's Gamble
Merck's Scientists Cave In To The Vogue of Surrogate Marker Endpoint Trials, Accelerated Approval And Quick Cash
- Souped-Up Abs from LTNPs
Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for "Bad" Cytokines; Parke-Davis Targets Cellular Factors
- February, 1995
- The CTL As Both Villain and Victor
Fascinating Work on HIV and T-Cell Kinetics Challenges Longtime Dismissal of Ravaged Immune System's Regenerative Potential
- Re-Inventing Government
New ACTG Structure Squeezes Eleven Committees Into Three--But Will Anything Really Be Any Different?
- Hope for Sale
Like the Wings of Icarus, Treatment Hype Sweeps Its prey Upward to the Heavens, Then Plucks Them Down Into icey Waters
- January, 1995
Back to the Treatment Action Group index page
|
|
